Investor Relations
Latest Financial Results
Q3 2024
Quarter Ended Sep 30, 2024
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2023
Report Links
Email Alerts
Sign up today and receive company updates straight to your inbox.
Company Overview
Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis (LN). The Company’s head office is in Edmonton, Alberta, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally.
IR Contacts
Company
Aurinia Pharmaceuticals Inc.
#140, 14315 – 118 Avenue
Edmonton, AB T5L 4S6
Canada
T: +1 (250) 744-2487
F: +1 (250) 708-4345
Investor Relations
Andrea Christopher
Executive Director, Corporate Communications & Investor Relations
achristopher@auriniapharma.com
General inquiries can also be sent to
ir@aurinapharma.com
Transfer Agent
Computershare Trust Company of Canada
Shareholder Services Dept.
100 University Avenue
9th Floor
Toronto, ON M5J 2Y1
Canada
T: +1-514-982-7555
service@computershare.com
https://www.computershare.com
